Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Weiner, Michael W. , Veitch, Dallas P. , Aisen, Paul, Cairns, Nigel J., Cedarbaum, Jesse M. , Donohue, Michael , Harvey, Danielle, Jack, Clifford R. , Jagust, William J. , Morris, John C. , Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Thompson, Paul M. , Trojanowski, John Q. , Initiative, Alzheimer's Disease Neuroimaging, Harvey, Danielle , Beckett, Laurel , Green, Robert C. , Harvey, Danielle, Toga, Arthur W. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Thompson, Paul M , Morris, John C , Donohue, Michael C , Harvey, Danielle J

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 865-884

10.1016/j.jalz.2015.04.005 | PMID 26194320 Get It

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post‐traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data‐sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public‐private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.
A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation
Yüksel, Muhammed , Wang, Yipeng, Tai, Ningwen , Guo, Junhua , Béland, Kathie , Lapierre, Pascal , David, Chella S., Colle, Isabelle , Yan, Huiping, Mieli‐Vergani, Giorgina , Vergani, Diego , Ma, Yun, Li, Wen , David, Chella, Wang, Yipeng, Peng, Jian , Álvarez, Fernando

Hepatology | July 16, 2015 | Volume: 62 | Issue: 5 | Pages: 1536-1550

10.1002/hep.27998 | PMID 26185095 Get It

Autoimmune hepatitis (AIH) in humans is a severe inflammatory liver disease characterized by interface hepatitis, the presence of circulating autoantibodies, and hyper‐gammaglobulinemia. There are two types of AIH, type 1 (AIH‐1) and type 2 (AIH‐2), characterized by distinct autoimmune serology. Patients with AIH‐1 are positive for anti–smooth muscle and/or antinuclear autoantibodies, whereas patients with AIH‐2 have anti–liver kidney microsomal type 1 and/or anti–liver cytosol type 1 autoantibodies. Cytochrome P4502D6 is the antigenic target of anti–liver kidney microsomal type 1, and formiminotransferase cyclodeaminase is the antigenic target of anti–liver cytosol type 1. It is known that AIH, both types 1 and 2, is strongly linked to the human leukocyte antigen (HLA) alleles ‐DR3, ‐DR4, and ‐DR7. However, direct evidence of the association of HLA with AIH is lacking. We developed a novel mouse model of AIH using the HLA‐DR3 transgenic mouse on the nonobese‐diabetic background by immunization of HLA‐DR3– and HLA‐DR3+ nonobese‐diabetic mice with a DNA plasmid, coding for human cytochrome P4502D6/formiminotransferase cyclodeaminase fusion protein. Immunization with cytochrome P4502D6/formiminotransferase cyclodeaminase leads to a sustained elevation of alanine aminotransferase, development of antinuclear autoantibodies and anti–liver kidney microsomal type 1/anti–liver cytosol type 1 autoantibodies, chronic immune cell infiltration, and parenchymal fibrosis on liver histology in HLA‐DR3+ mice. Immunized mice also showed an enhanced T helper 1 immune response and paucity of the frequency of regulatory T cells in the liver. Moreover, HLA‐DR3+ mice with exacerbated AIH showed reduced diversity and total load of gut bacteria. Conclusion: Our humanized animal model has provided a novel experimental tool to further elucidate the pathogenesis of AIH and to evaluate the efficacy and safety of immunoregulatory therapeutic interventions in vivo. (Hepatology 2015;62:1536–1550)
Accuracy of a Tablet Audiometer for Measuring Behavioral Hearing Thresholds in a Clinical Population
Thompson, Gregory P., Sladen, Douglas P. , Borst, Becky J. Hughes, Still, Owen L.

Otolaryngology–Head and Neck Surgery | July 16, 2015 | Volume: 153 | Issue: 5 | Pages: 838-842

10.1177/0194599815593737 | PMID 26183518 Get It

Objective To examine the validity of a tablet computer–based audiometer for measuring hearing thresholds in a moderately noisy environment. Study Design A prospective single‐cohort repeated measures study. Setting Tertiary care institution providing hearing health care to a diverse population. Subjects and Methods Subjects included 49 participants (44 adults, 5 children) with all degrees of hearing sensitivity. Potential participants were excluded if they were <4 years old or had cognitive deficits or ear drainage. Participants were tested with established audiometric tests and a tablet audiometer. Threshold values were measured for both ears using various stimuli (500, 1000, 2000, and 4000 Hz). Testing with the tablet audiometer was conducted in a non‐sound‐treated room; room properties were characterized by ambient noise level and reverberation testing. Calibration assessment of the tablet audiometer was performed on 3 occasions. Results Within the test thresholds for hearing level, results from the tablet device were within 10 dB of those determined by conventional audiometry for 164 of 172 hearing levels and did not show proportional bias over the testing range. Calibration assessment showed accurate proximity between output and target values, though crosstalk and linearity failed initial assessments. Conclusion The tablet‐based automated audiometer presents a new method for threshold hearing assessment outside conventional sound booths.
Ranolazine inhibits voltage-gated mechanosensitive sodium channels in human colon circular smooth muscle cells
Neshatian, Leila , Strege, Peter R. , Rhee, Poong‐Lyul , Kraichely, Robert E., Mazzone, Amelia , Bernard, Cheryl E., Dozois, Eric J. , Kline, Crystal F., Mohler, Peter J. , Farrugia, Gianrico , Cima, Robert R. , Larson, David W. , Beyder, Arthur , Strege, Peter R , Mazzone, Amelia , Neshatian, Leila

American Journal of Physiology-Gastrointestinal and Liver Physiology | July 16, 2015 | Volume: 309 | Issue: 6 | Pages: G506-G512

10.1152/ajpgi.00051.2015 | PMID 26185330 Get It

Human jejunum smooth muscle cells (SMCs) and interstitial cells of Cajal (ICCs) express the SCN5A-encoded voltage-gated, mechanosensitive sodium channel NaV1.5. NaV1.5 contributes to small bowel excitability, and NaV1.5 inhibitor ranolazine produces constipation by an unknown mechanism. We aimed to determine the presence and molecular identity of Na+ current in the human colon smooth muscle and to examine the effects of ranolazine on Na+ current, mechanosensitivity, and smooth muscle contractility. Inward currents were recorded by whole cell voltage clamp from freshly dissociated human colon SMCs at rest and with shear stress. SCN5A mRNA and NaV1.5 protein were examined by RT-PCR and Western blots, respectively. Ascending human colon strip contractility was examined in a muscle bath preparation. SCN5A mRNA and NaV1.5 protein were identified in human colon circular muscle. Freshly dissociated human colon SMCs had Na+ currents (−1.36 ± 0.36 pA/pF), shear stress increased Na+ peaks by 17.8 ± 1.8% and accelerated the time to peak activation by 0.7 ± 0.3 ms. Ranolazine (50 μM) blocked peak Na+ current by 43.2 ± 9.3% and inhibited shear sensitivity by 25.2 ± 3.2%. In human ascending colon strips, ranolazine decreased resting tension (31%), reduced the frequency of spontaneous events (68%), and decreased the response to smooth muscle electrical field stimulation (61%). In conclusion, SCN5A-encoded NaV1.5 is found in human colonic circular smooth muscle. Ranolazine blocks both peak amplitude and mechanosensitivity of Na+ current in human colon SMCs and decreases contractility of human colon muscle strips. Our data provide a likely mechanistic explanation for constipation induced by ranolazine.
En Bloc Resection of Solitary Functional Secreting Spinal Metastasis
Gokaslan, Ziya L. , Fisher, Charles G. , Laufer, Ilya , Weber, Michael H. , Sciubba, Daniel M. , Goodwin, C. Rory , Clarke, Michelle J.

Global Spine Journal | July 16, 2015 | Volume: 6 | Issue: 3 | Pages: 277-283

10.1055/s-0035-1558654 | PMID 27099819 Get It

Study Design Literature review. Objective Functional secretory tumors metastatic to the spine can secrete hormones, growth factors, peptides, and/or molecules into the systemic circulation that cause distinct syndromes, clinically symptomatic effects, and/or additional morbidity and mortality. En bloc resection has a limited role in metastatic spine disease due to the current paradigm that systemic burden usually determines morbidity and mortality. Our objective is to review the literature for studies focused on en bloc resection of functionally active spinal metastasis as the primary indication. Methods A review of the PubMed literature was performed to identify studies focused on functional secreting metastatic tumors to the spinal column. We identified five cases of patients undergoing en bloc resection of spinal metastases from functional secreting tumors. Results The primary histologies of these spinal metastases were pheochromocytoma, carcinoid tumor, choriocarcinoma, and a fibroblast growth factor 23–secreting phosphaturic mesenchymal tumor. Although studies of en bloc resection for these rare tumor subtypes are confined to case reports, this surgical treatment option resulted in metabolic cures and decreased clinical symptoms postoperatively for patients diagnosed with solitary functional secretory spinal metastasis. Conclusion Although the ability to formulate comprehensive conclusions is limited, case reports demonstrate that en bloc resection may be considered as a potential surgical option for the treatment of patients diagnosed with solitary functional secretory spinal metastatic tumors. Future prospective investigations into clinical outcomes should be conducted comparing intralesional resection and en bloc resection for patients diagnosed with solitary functional secretory spinal metastasis.
Gait Emulator for Evaluation of Ankle–Foot Prostheses Capable of Turning1
Ficanha, Evandro M., Kaufman, Kenton R. , Rastgaar, Mo , Kaufman, Kenton R

Journal of Medical Devices | July 16, 2015 | Volume: 9 | Issue: 3 | Pages: No page available

10.1115/1.4030546 Get It

Therapy-Related Myeloid Neoplasms
Bueso‐Ramos, Carlos E. , Kanagal‐Shamanna, Rashmi , Hanson, Curtis A. , Routbort, Mark J. , Kanagal-Shamanna, Rashmi

American Journal of Clinical Pathology | July 16, 2015 | Volume: 144 | Issue: 2 | Pages: 207-218

10.1309/ajcpu1jo2lytwuav | PMID 26185306 Get It

AbstractObjectivesIn the 2008 World Health Organization classification, cases of acute myeloid leukemia (AML) and myelodysplastic syndrome that arise after chemotherapy or radiation therapy for a primary neoplasm are considered together as therapy-related myeloid neoplasms (TR-MNs). This concept, however, is not universally accepted since there are confounding variables in attributing myeloid neoplasms to earlier therapies.MethodsCases in session 6 of the 2013 Workshop of the Society for Hematopathology/European Association for Haematopathology illustrated myeloid neoplasms thought likely to be TR-MNs, and discussed the differences and biologic similarities with de novo myeloid neoplasms.ResultsWe reviewed data showing that diagnosis of TR-MN alters patient outcome only in specific subsets. The session also included examples of therapy-related AML with recurrent genetic abnormalities, such as t(15;17), inv(16), and t(8;21), and reports were highlighted showing that patients with these neoplasms have clinical outcomes similar to patients with their de novo counterparts.ConclusionsThe study of TR-MNs will likely provide insight into the pathogenesis of de novo myeloid disease and may explain why some patients with cancer develop TR-MN and evidently have a higher genetic susceptibility, whereas most patients treated with the same agents do not. These studies will also result in critical reappraisal of current concepts related to TR-MNs.
Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol
Bhat, Mamatha , Hathcock, Matthew , Kremers, Walter K. , Murad, Sarwa Darwish , Schmit, Grant D. , Martenson, James A., Rosen, Charles B. , Darwish Murad, Sarwa, Schmit, Grant, Martenson, James, Alberts, Steven, Alberts, Steven R. , Gores, Gregory J. , Heimbach, Julie K. , Bhat, Mamatha , Kremers, Walter K , Darwish Murad, Sarwa

Transplant International | July 16, 2015 | Volume: 28 | Issue: 12 | Pages: 1383-1391

10.1111/tri.12640 | PMID 26183487 Get It

Effects of lubricant and autologous bone marrow stromal cell augmentation on immobilized flexor tendon repairs
Zhao, Chunfeng , Ozasa, Yasuhiro , Shimura, Haruhiko , Reisdorf, Ramona L., Thoreson, Andrew R. , Jay, Gregory D. , Moran, Steven L. , An, Kai‐Nan, Amadio, Peter C. , An, Kai‐Nan

Journal of Orthopaedic Research | July 16, 2015 | Volume: 34 | Issue: 1 | Pages: 154-160

10.1002/jor.22980 | PMID 26177854 Get It

ABSTRACTThe purpose of the study was to test a novel treatment that carbodiimide‐derivatized‐hyaluronic acid‐lubricin (cd‐HA‐lubricin) combined cell‐based therapy in an immobilized flexor tendon repair in a canine model. Seventy‐eight flexor tendons from 39 dogs were transected. One tendon was treated with cd‐HA‐lubricin plus an interpositional graft of 8 × 105 BMSCs and GDF‐5. The other tendon was repaired without treatment. After 21 day of immobilization, 19 dogs were sacrificed; the remaining 20 dogs underwent a 21‐day rehabilitation protocol before euthanasia. The work of flexion, tendon gliding resistance, and adhesion score in treated tendons were significantly less than the untreated tendons (p < 0.05). The failure strength of the untreated tendons was higher than the treated tendons at 21 and 42 days (p < 0.05). However, there is no significant difference in stiffness between two groups at day 42. Histologic analysis of treated tendons showed a smooth surface and viable transplanted cells 42 days after the repair, whereas untreated tendons showed severe adhesion formation around the repair site. The combination of lubricant and cell treatment resulted in significantly improved digit function, reduced adhesion formation. This novel treatment can address the unmet needs of patients who are unable to commence an early mobilization protocol after flexor tendon repair. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:154–160, 2016.
SynCardia Portable Freedom Driver: A Single-Center Experience with 11 Patients
Jaroszewski, Dawn E. , Schroedl, L., Staley, Linda L., Pajaro, Octavio E., Kasirajan, Vigneshwar , Arabía, Francisco A. , Shah, Nilay R, Shah, Nilay R. , Ashfaq, Awais

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | July 16, 2015 | Volume: 10 | Issue: 3 | Pages: 188-194

10.1097/imi.0000000000000161 | PMID 26181585 Get It

Objective The portable Freedom Drive (SynCardia Inc, Tucson, AZ USA) for total artificial heart (TAH-t) support was approved for an investigational device exemption study in March 2010. We review our center's experience with the portable driver. Methods A retrospective review was conducted of patients who underwent TAH-t implantation and transfer to portable driver from September 2008 to June 2012, with follow-up through December 2012. Results A total of 30 patients underwent TAH-t implantation during this time period, with 11 patients successfully transferred to the Freedom Driver. Transfer to Freedom Driver after TAH-t implant was a median of 46 days (range, 225–86 days). Ninety-one percent (10) of 11 patients transferred to Freedom Driver were bridged to transplantation. One patient died on support. Five (45.5%) of 11 patients were discharged home and 5 (45.5%) remained in-patient on the portable driver before transplantation. Four patients (80%) successfully discharged home required at least 1 hospital readmission (range, 1–5 admissions per patient). Six patients (55%) transferred to the portable driver required a return to a main driver console. Two patients were temporarily maintained on the main driver then returned to the Freedom Driver for bridge to transplantation. Conclusions Patients with TAH-t can be considered for transfer to the portable Freedom Driver while awaiting transplantation. Issues that complicated this patient population included inadequate social support, hemodynamic instability, and concurrent morbidities. The potential benefits of the portable driver are currently undergoing assessment. These may include increased mobility and improved quality of life, opportunity for discharge home, and decreased overall medical costs.